This study demonstrates that complementary afferent and cortical physiological abnormalities in FRDA can be non-invasively quantified within individuals. These MEG-derived measures provide a physiological framework for investigating disease heterogeneity and candidate biomarkers for monitoring disease progression and therapeutic interventions.